Recordati SpAMIL:REC 94 PS Ratio is 4.06 as of Jun. 30, 2026, which is 21% below its 10-year median of 5.12. GuruFocus rates MIL:REC with a GF Score™ of 94/100 and a GF Value™ of €60.65 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 948 Drug Manufacturers companies, Recordati SpA ranks worse than 68.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Recordati SpA's share price is €51.50.
Recordati SpA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €12.68. Hence, Recordati SpA's PS Ratio for today is 4.06.
The historical rank and industry rank for Recordati SpA's PS Ratio or its related term are showing as below:
MIL:REC'
s PS Ratio Range Over the Past 10 Years
Min: 3.57 Med: 5.12 Max: 8.23
Current: 4.06
During the past 13 years, Recordati SpA's highest PS Ratio was 8.23. The lowest was 3.57. And the median was 5.12.
MIL:REC's PS Ratio is ranked worse than 68.67% of 948
companies
in the Drug Manufacturers industry
Industry Median: 2.205
vs MIL:REC: 4.06
Recordati SpA has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Recordati SpA was 9.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 9.10% per year.
During the past 13 years, Recordati SpA's highest 3-Year average Revenue per Share Growth Rate was 14.00% per year. The lowest was 1.20% per year. And the median was 8.20% per year.
Back to Basics: PS Ratio
Recordati SpA (MIL:REC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Recordati SpA PS Ratio Related Terms
Recordati SpA PS Ratio Historical Data
* Premium members only.
The historical data trend for Recordati SpA's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Recordati SpA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Recordati SpA's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Recordati SpA's Share Price of today is €51.50. Recordati SpA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Recordati SpA (MIL:REC) has a PS Ratio of 4.06 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Recordati SpA and its competitors. This is 21% below median its historical median of 5.12. Over the past decade, Recordati SpA's PS Ratio has ranged from 3.57 to 8.23. According to the industry distribution chart, Recordati SpA ranks #651 out of 948 companies in the Drug Manufacturers industry, placing it in the top 68.7%.
Is Recordati SpA's PS Ratio too high?
Recordati SpA's current PS Ratio of 4.06 is 21% below median its 10-year median of 5.12. Over the past 10 years, this metric has ranged from a low of 3.57 to a high of 8.23. The Drug Manufacturers industry median PS Ratio is 2.21. Recordati SpA's value of 4.06 is 84.1% above this industry median. Based on the distribution chart, Recordati SpA ranks #651 out of 948 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #651 out of 948 companies for PS Ratio. This places Recordati SpA in the lower half of its industry. The industry median PS Ratio is 2.21. Recordati SpA's value of 4.06 is 84.1% above this benchmark. Historically, Recordati SpA's own PS Ratio has ranged from 3.57 to 8.23 over the past decade. While the company's 10-year median is 5.12 vs. the industry median of 2.21, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.21, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current PS Ratio of 4.06 is 84.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current PS Ratio is 4.06, which is 21% below median its own 10-year median of 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.65, compared to a current price of €51.50 — trading 15.1% below its estimated fair value. The current PS Ratio is 4.06, which is 21% below median its 10-year median of 5.12 and 84.1% above the Drug Manufacturers industry median of 2.21. Recordati SpA's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current PS Ratio is 4.06 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.50 is trading 15.1% below its estimated GF Value™ of €60.65.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
PS Ratio: 4.06 (21% below median its 10-year median of 5.12)
GF Value™: €60.65 vs. price of €51.50 (15.1% below fair value)
Industry Position: 84.1% above the Drug Manufacturers median (#651 of 948)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
94GF Score
Get the complete analysis for MIL:REC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
